• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oculis Holding AG - Ordinary shares (NQ:OCS)

27.22 -0.26 (-0.95%)
Streaming Delayed Price Updated: 1:29 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oculis Holding AG - Ordinary shares

< Previous 1 2 3 Next >
News headline image
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Today 4:00 EDT
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Publishes Invitation to the Annual General Meeting
April 21, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
April 20, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming Investor Conferences
April 07, 2026
From Oculis Holding AG
Via GlobeNewswire
Oculis Holding AG (NASDAQ:OCS) Reports Q4 2025 Earnings Beat, Focus Remains on 2026 Clinical Catalysts ↗
March 03, 2026
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 6, 2025 ↗
November 06, 2025
 
Via Benzinga
News headline image
Uncovering Potential: Oculis Holding's Earnings Preview ↗
August 20, 2025
 
Via Benzinga
News headline image
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
March 31, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
March 16, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming Investor Conferences
March 05, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
March 03, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Appoints Katie Kazem as Chief Legal Officer
February 17, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
January 08, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
January 06, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
November 11, 2025
 
Via Benzinga
News headline image
Oculis Holding AG (NASDAQ:OCS) Reports Q3 2025 Earnings Beat and Provides Key Clinical Pipeline Updates ↗
November 10, 2025
Oculis (OCS) beat Q3 2025 earnings estimates, extended cash runway into 2029, and advanced its late-stage ophthalmology pipeline with key clinical milestones ahead. 
Via Chartmill
Topics Earnings
News headline image
Oculis Reports Q3 2025 Financial Results and Provides Company Update
November 10, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming November Investor Conferences
November 05, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
October 30, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
October 14, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
October 08, 2025
 
Via Benzinga
News headline image
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
October 06, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
September 22, 2025
Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial 
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
September 04, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
September 01, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming September Investor Conferences
August 28, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
This CoreWeave Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
August 27, 2025
 
Via Benzinga
News headline image
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
August 25, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Reports Q2 2025 Financial Results and Provides Company Update
August 21, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Earnings Scheduled For August 21, 2025 ↗
August 21, 2025
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap